Urological cancers

Therapy with the PARP inhibitor olaparib delayed cancer progression in patients with metastatic, pre-treated prostate cancer with loss-of-function alterations in HRR genes by about four months compared to new hormonal agents (enzalutamide or abiraterone acetate).

Data from two new studies presented at ESMO 2019 show that clinical benefit of adjuvant radiotherapy does not outweigh the potential risk of side effects.

Am ESMO präsentierte aktuelle Daten zweier Studien zeigen deutlich, dass der klinische Nutzen einer adjuvanten Radiotherapie das Risiko potenzieller Nebenwirkungen nicht überwiegt.